ÂÜÀòÂÒÂ×

Benjamin Andreone is a Senior Scientist II and Project Lead at Atalanta Therapeutics, where responsibilities include leading two preclinical pipeline programs involving target validation, compound screening, lead selection, mechanism of action, and IND-enabling studies since October 2020. Previously, Benjamin held multiple project lead roles at Denali Therapeutics from January 2018 to September 2020, focusing on neurodegenerative disease mechanisms and contributing significant findings regarding PLCG2's role in microglial function. Academic training includes a Ph.D. in Neuroscience from Harvard Medical School, with research on blood-brain barrier molecular mechanisms, and a Bachelor's Degree in Biology from the University of Maryland. Complementing this educational background, experience as a Research Associate at Johns Hopkins School of Medicine was also attained.